In August 2025, InSilico Medicine Hong Kong Limited announced a clinical trial is to learn about INS018_055 in adults with ...

Contineum Therapeutics has pumped the brakes on two projects, freeing up resources to go full speed ahead in its pursuit of Bristol Myers Squibb in idiopathic pulmonary fibrosis.

A new AI tool helps predict survival in fibrotic lung disease, outperforming traditional clinical and imaging methods in a study of over 1,200 patients.

MannKind saw decent growth from its two core products in Q2 and just signed a new non-dilutive financing agreement with ...

"We are extremely excited about forming this important collaboration between our companies and scientists that will empower ...

These 10 stocks could mint the next wave of millionaires › Contineum Therapeutics (NASDAQ:CTNM), a clinical-stage biotechnology company focused on developing treatments for serious diseases such as ...

Key Points Revenue grew 10% year-over-year to $10.8 million (GAAP) in Q2 2025, reflecting continued top-line gains, with GAAP net revenues of $10.8 million. Adjusted diluted earnings per share ...

Cumberland Pharmaceuticals Inc (CPIX) reports a 10% revenue increase and strategic international expansions, despite facing ...

Senolytic Supplements Market to Reach $350 Million by 2025, Poised for 15% CAGR Through 2032 Driven by growing focus on healthy aging and breakthroughs in cellular senescence-targeted therapies The ...

Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readoutsAleniglipron clinical development program expanded to optimize ...

GRI-0621 appears to reduce markers of fibrosis in people with idiopathic pulmonary fibrosis, interim clinical trial data ...

Anita battled a persistent cough for years, now the Queensland mum is grateful for a second chance at life thanks to a ...